{
  "query": "AZN",
  "resolved": {
    "ticker": "AZN",
    "cik": "0000901832",
    "title": "ASTRAZENECA PLC"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE2 primary completion in ~140 days",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
        "nctId": "NCT04482309",
        "date": "2027-03-23"
      },
      "observed": {
        "event": "primary completion in ~140 days",
        "nctId": "NCT04482309"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT04482309",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus",
        "nctId": "NCT07784725",
        "date": "2028-08-11"
      },
      "observed": {
        "event": "protocol updated 4 days ago",
        "nctId": "NCT07784725"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07784725",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 6 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight",
        "nctId": "NCT07784270",
        "date": "2028-08-09"
      },
      "observed": {
        "event": "protocol updated 6 days ago",
        "nctId": "NCT07784270"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07784270",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus",
        "nctId": "NCT07662109",
        "date": "2028-07-05"
      },
      "observed": {
        "event": "protocol updated 4 days ago",
        "nctId": "NCT07662109"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07662109",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "ASTRAZENECA PLC",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": []
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-11-03T09:00:20.748Z"
}